These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32189402)

  • 1. Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.
    Morita A; Tateishi C; Muramatsu S; Kubo R; Yonezawa E; Kato H; Nishida E; Tsuruta D
    J Dermatol; 2020 May; 47(5):443-451. PubMed ID: 32189402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma.
    Morita A; Tateishi C; Ikumi K; Hayashi D; Nakada A; Nishihara H; Torii K; Nishida E; Tsuruta D
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):615-629. PubMed ID: 35084694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP; Levitan D; Fleischer AB
    J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201).
    Hamada T; Tokura Y; Sugaya M; Ohtsuka M; Tsuboi R; Nagatani T; Kiyohara E; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Saida T; Iwatsuki K
    J Dermatol; 2019 Jul; 46(7):557-563. PubMed ID: 31090237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy.
    Fujimura T; Sato Y; Tanita K; Amagai R; Shimauchi T; Ogata D; Fukushima S; Miyashita A; Fujisawa Y; Kambayashi Y; Aiba S
    J Dermatol; 2020 Jun; 47(6):636-640. PubMed ID: 32207181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
    Bohmeyer J; Stadler R; Kremer A; Nashan D; Muche M; Gellrich S; Luger T; Sterry W
    J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma.
    Straus DJ; Duvic M; Horwitz SM; Hymes K; Goy A; Hernandez-Ilizaliturri FJ; Feldman T; Wegner B; Myskowski PL
    Ann Oncol; 2014 Jan; 25(1):206-10. PubMed ID: 24285015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
    Illidge T; Chan C; Counsell N; Morris S; Scarisbrick J; Gilson D; Popova B; Patrick P; Smith P; Whittaker S; Cowan R
    Br J Cancer; 2013 Nov; 109(10):2566-73. PubMed ID: 24136145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The optimal use of bexarotene in cutaneous T-cell lymphoma.
    Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
    Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.
    Stadler R; Otte HG; Luger T; Henz BM; Kühl P; Zwingers T; Sterry W
    Blood; 1998 Nov; 92(10):3578-81. PubMed ID: 9808550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma.
    Sanagawa A; Hayakawa T; Yamamoto A; Hotta Y; Furukawa-Hibi Y; Morita A
    Drugs R D; 2024 Jun; 24(2):227-238. PubMed ID: 38871976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
    Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
    J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal combination with PUVA: rationale and clinical trial update.
    Stadler R
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):29-32. PubMed ID: 17474357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
    Breneman D; Duvic M; Kuzel T; Yocum R; Truglia J; Stevens VJ
    Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance.
    Hamada T; Morita A; Suga H; Boki H; Fujimura T; Hirai Y; Shimauchi T; Tateishi C; Kiyohara E; Muto I; Nakajima H; Abe R; Fujii K; Nishigori C; Nakano E; Yonekura K; Funakoshi T; Amano M; Miyagaki T; Makita N; Manaka K; Shimoyama Y; Sugaya M
    J Dermatol; 2022 Feb; 49(2):253-262. PubMed ID: 34658060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
    Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
    J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
    Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
    Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
    Singh F; Lebwohl MG
    J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
    Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.